HEALWELL AI Sets March Dates to Release 2025 Results and Brief Investors
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HEALWELL AI ( (TSE:AIDX) ) has shared an update.
HEALWELL AI Inc., a healthcare artificial intelligence firm specializing in preventative care and clinical decision support tools, leverages proprietary technology to help clinicians detect rare and chronic diseases earlier and manage patient care more efficiently. The company is publicly traded in Canada and the U.S., reflecting its growing presence in the digital health and AI-enabled diagnostics market.
HEALWELL AI announced it will release its fiscal fourth quarter and full-year 2025 financial results for the period ended December 31, 2025, on March 19, 2026. Management will host a conference call and simultaneous webcast the following day, March 20, 2026, giving investors and analysts an opportunity to review the company’s performance and outlook with senior leadership.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
Spark’s Take on TSE:AIDX Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIDX is a Neutral.
The score is held back primarily by weak financial performance (large losses and negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). The latest earnings call provides a meaningful offset with strong integration-driven revenue growth and positive adjusted EBITDA, but valuation remains constrained by losses and there is no dividend support.
To see Spark’s full report on TSE:AIDX stock, click here.
More about HEALWELL AI
HEALWELL AI Inc. is a healthcare artificial intelligence company focused on preventative care and early disease detection. Using proprietary technology, it develops and commercializes advanced clinical decision support systems that help providers identify rare and chronic diseases, improve practice efficiency, and enhance patient outcomes. The company pursues a strategy of developing and acquiring complementary technology and clinical sciences capabilities and is listed on the Toronto Stock Exchange under AIDX and on the OTC market under HWAIF.
Average Trading Volume: 563,643
Technical Sentiment Signal: Sell
Current Market Cap: C$308.7M
Learn more about AIDX stock on TipRanks’ Stock Analysis page.
